We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Alkermes’s OLZ/SAM Gets Green Light From FDA Advisory Committees
Alkermes’s OLZ/SAM Gets Green Light From FDA Advisory Committees
Two FDA expert panels voted in favor of FDA approval for Alkermes’s new drug application (NDA) for its schizophrenia and bipolar disorder investigational drug OLZ/SAM (olanzapine/samidorphan) in a joint session on Friday.